Blocking endocannabinoid breakdown reduced opioid withdrawal symptoms in mice
Mice given drugs that boosted their natural endocannabinoids showed fewer opioid withdrawal symptoms, with the 2-AG pathway showing broader effects than anandamide.
Quick Facts
What This Study Found
Morphine-dependent mice challenged with naloxone displayed jumping, paw tremors, diarrhea, and weight loss. The researchers tested two strategies to boost endocannabinoids: blocking MAGL (which breaks down 2-AG) and blocking FAAH (which breaks down anandamide).
The MAGL inhibitor JZL184 reduced most withdrawal symptoms in a dose-dependent manner through CB1 receptors. It also reduced spontaneous withdrawal signs, not just those triggered by naloxone.
The FAAH inhibitor PF-3845 reduced jumping and paw tremors through CB1 receptors but did not help with diarrhea or weight loss. This suggested 2-AG and anandamide play different roles in opioid withdrawal.
Key Numbers
JZL184 dose-dependently reduced most withdrawal symptoms. PF-3845 reduced jumping and paw tremors but not diarrhea or weight loss. Both effects were blocked by CB1 antagonist rimonabant, confirming the mechanism.
How They Did This
Morphine-dependent mice received naloxone to precipitate withdrawal. Researchers tested MAGL inhibitor JZL184 and FAAH inhibitor PF-3845 at multiple doses, using CB1 and CB2 antagonists to confirm receptor mechanisms. An isolated ileum preparation tested gut-level effects.
Why This Research Matters
Opioid withdrawal is a major barrier to quitting. These findings suggested that boosting the body's own cannabinoids, rather than using external cannabis, could reduce withdrawal severity while potentially avoiding the side effects of direct cannabinoid agonists.
The Bigger Picture
This study contributed to a growing body of evidence connecting the endocannabinoid and opioid systems. The approach of boosting natural endocannabinoids rather than administering external cannabinoids represents a more targeted therapeutic strategy.
What This Study Doesn't Tell Us
Mouse study only. The doses and routes of administration may not translate to humans. Naloxone-precipitated withdrawal is more abrupt than natural withdrawal. Long-term effects of endocannabinoid enzyme inhibition were not assessed.
Questions This Raises
- ?Would MAGL inhibitors work in human opioid withdrawal?
- ?Could combining FAAH and MAGL inhibitors produce broader symptom relief?
- ?What are the long-term safety implications of sustained endocannabinoid elevation?
Trust & Context
- Key Stat:
- MAGL inhibitor reduced most withdrawal symptoms; FAAH inhibitor helped only some
- Evidence Grade:
- Animal study with clear mechanistic findings. Strong internal design with receptor antagonist controls, but no human data.
- Study Age:
- Published in 2011. Research on endocannabinoid enzyme inhibitors for addiction has continued to develop.
- Original Title:
- Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.
- Published In:
- The Journal of pharmacology and experimental therapeutics, 339(1), 173-85 (2011)
- Authors:
- Ramesh, Divya(6), Ross, Gracious R, Schlosburg, Joel E(7), Owens, Robert A, Abdullah, Rehab A, Kinsey, Steven G, Long, Jonathan Z, Nomura, Daniel K, Sim-Selley, Laura J, Cravatt, Benjamin F, Akbarali, Hamid I, Lichtman, Aron H
- Database ID:
- RTHC-00512
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Is this the same as using cannabis for opioid withdrawal?
No. Instead of introducing external cannabinoids, this approach boosts the body's own endocannabinoids by blocking the enzymes that break them down. This is a more targeted strategy that may avoid some side effects of cannabis use.
Why did the two approaches work differently?
Anandamide (boosted by FAAH inhibition) and 2-AG (boosted by MAGL inhibition) act on overlapping but different pathways. 2-AG is present at higher concentrations and may have broader effects on withdrawal symptoms.
Read More on RethinkTHC
- 30-days-without-weed
- 6-months-sober-weed-what-to-expect
- 90-days-no-weed
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- benefits-of-quitting-weed
- boredom-after-quitting-weed
- boredom-after-quitting-weed-nothing-fun
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- creativity-without-weed-quitting-artist-musician
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- hobbies-after-quitting-weed
- identity-after-quitting-weed
- leaving-stoner-culture-identity
- money-saved-quitting-weed-calculator
- nervous-system-weed-withdrawal-fight-flight
- one-year-sober-weed
- quitting-weed-creativity
- quitting-weed-face-changes-skin
- quitting-weed-weight-loss-gain
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
- thc-and-antibiotics-safe-cannabis-while-on
- thc-and-caffeine-most-common-drug-combo
- thc-and-diabetes-medication-blood-sugar
Cite This Study
https://rethinkthc.com/research/RTHC-00512APA
Ramesh, Divya; Ross, Gracious R; Schlosburg, Joel E; Owens, Robert A; Abdullah, Rehab A; Kinsey, Steven G; Long, Jonathan Z; Nomura, Daniel K; Sim-Selley, Laura J; Cravatt, Benjamin F; Akbarali, Hamid I; Lichtman, Aron H. (2011). Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.. The Journal of pharmacology and experimental therapeutics, 339(1), 173-85. https://doi.org/10.1124/jpet.111.181370
MLA
Ramesh, Divya, et al. "Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.." The Journal of pharmacology and experimental therapeutics, 2011. https://doi.org/10.1124/jpet.111.181370
RethinkTHC
RethinkTHC Research Database. "Blockade of endocannabinoid hydrolytic enzymes attenuates pr..." RTHC-00512. Retrieved from https://rethinkthc.com/research/ramesh-2011-blockade-of-endocannabinoid-hydrolytic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.